{"product_id":"cst-91213sf","title":"CST,  91213SF, CD20 (Rituximab Biosimilar) Human Monoclonal Antibody","description":"Monoclonal Antibody for studying CD20. Validated for Neutralizing. Highly specific and rigorously validated in-house, CD20 (Rituximab Biosimilar) Human Monoclonal Antibody (CST #91213) is ready to ship.\n\n\u003cb\u003eProduct Usage Information\u003c\/b\u003e\nThis product is intended for research use only (RUO). Optimal dilutions\/concentrations should be determined by the end user.\n\u003cb\u003eFormulation\u003c\/b\u003e\nSupplied in 1X PBS, BSA and Azide Free.\n\u003cb\u003eStorage\u003c\/b\u003e\nStore at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze\/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance.\n\u003cb\u003eSpecificity \/ Sensitivity\u003c\/b\u003e\nCD20 (Rituximab Biosimilar) Human Monoclonal Antibody was confirmed to bind to its intended target protein CD20 using flow cytometry.\nSpecies Reactivity: Human\n\u003cb\u003eSource \/ Purification\u003c\/b\u003e\nCD20 (Rituximab Biosimilar) Human mAb is produced at Cell Signaling Technology. Rituximab is an antibody directed against the extracellular region of human CD20.\n\u003cb\u003eBackground\u003c\/b\u003e\nB-lymphocyte antigen CD20 (also known as MS4A1; Membrane-spanning 4-domains subfamily A member 1) is a cell surface phosphoprotein involved in the regulation of B cell activation and proliferation (1,2). It is commonly used as a marker to identify B cells and is expressed throughout B cell development, up until their differentiation into plasma cells. CD20 has no known ligand, and its expression and function are largely conserved between human and mouse (1-3). Evidence suggests that CD20 is necessary for store operated calcium (SOC) entry, which leads to elevated cytoplasmic calcium levels required for B cell activation (4,5). Anti-CD20 antibody immunotherapy depletes B cells by activation of the innate monocytic network and is a common treatment for B cell lymphomas, leukemias, and autoimmune diseases (6).\n\u003cb\u003eAlternate Names\u003c\/b\u003e\nB-lymphocyte antigen CD20; B-lymphocyte cell-surface antigen B1; B-lymphocyte surface antigen B1; B1; Bp35; CD20; CD20 antigen; CD20 receptor; CVID5; LEU-16; Leukocyte surface antigen Leu-16; membrane spanning 4-domains A1; Membrane-spanning 4-domains subfamily A member 1; membrane-spanning 4-domains, subfamily A, member 1; MGC3969; MS4A1; MS4A2; S7\n\n\u003cb\u003eSpecification\u003c\/b\u003e\n\nREACTIVITY: H\nSENSITIVITY: Endogenous\nSource\/Isotype: Human IgG1 kappa","brand":"CST","offers":[{"title":"Default Title","offer_id":46800332390569,"sku":"91213SF","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/cst-91213sf","provider":"Iright","version":"1.0","type":"link"}